Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- Launching of Novel Anticoagulants Welcomed: JCS Symposium
August 29, 2011
- Radioactive Cesium Detected from RDF Incineration Ashes at Chugai's Research Lab
August 29, 2011
- St. Marianna Univ. Hospital Group Saves over ¥600 Mil. in Drug Expenditures by Using Generics
August 29, 2011
- Takeda to Increase No. of MRs to 2,000 in China
August 29, 2011
- Concrete Disclosure Standards Should Have Been Included in JPMA's GLs for COI: Prof. Miyata
August 29, 2011
- Eisai Subsidiary's CT Colonography System Receives Approval in Japan
August 29, 2011
- Actos Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
August 29, 2011
- Korosho to Grant Subsidies to 4 Companies to Develop, Manufacture New Flu Vaccines
August 29, 2011
- Use Medicoeconomic Evaluation in NHI Drug Pricing: Korosho Study Group
August 29, 2011
- Novartis Pharma to Ask Korosho Why It Was Not Selected for Vaccine Grant
August 29, 2011
- Yakult Gains Option Rights to Anticancer Drug from Proacta
August 15, 2011
- EC Approves Acquisition of Nycomed by Takeda
August 15, 2011
- First Aid for Choking
August 15, 2011
- Bayer Obtains Exclusive License for Novel Antibiotic
August 15, 2011
- Korosho Taking Public Comments on Proposed GL for Development of Prototype Pandemic Flu Vaccines
August 15, 2011
- RaQualia of Japan Aims to Become Global Drug Discovery Innovator
August 15, 2011
- Santen Creates Subsidiary in India
August 15, 2011
- Korosho Announces Revised Precautions for Diabetes Treatment Metgluco
August 15, 2011
- TOPICS 2 articles
August 15, 2011
- System to Ensure Early Price Settlement Necessary: Non-Partisan Council of Diet Members
August 15, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…